Literature DB >> 17289474

Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome.

Anne Kuitunen1, Raili Suojaranta-Ylinen, Peter Raivio, Sinikka Kukkonen, Riitta Lassila.   

Abstract

OBJECTIVE: The outcome of cardiac surgical patients with clinically diagnosed heparin-induced thrombocytopenia (HIT) was studied.
DESIGN: Retrospective, observational study.
SETTING: University hospital. PARTICIPANTS: All cardiac surgical patients with diagnosed HIT after cardiac surgery between January 2002 and December 2004, and concurrently, consecutive patients without HIT.
INTERVENTIONS: None Measurements and Main
Results: 3465 patients were treated postoperatively in the cardiac surgical intensive care unit during the study period. Clinical suspicion of HIT arose when platelet count markedly fell several days after surgery and HIT was proven by a positive enzyme immunoassay in 20 patients. Thrombocytopenia (35.5 [22] x 10(9)/L, median [interquartile range]) developed within 7 (6) days. HIT patients received significantly more platelet transfusions perioperatively than controls (p < 0.001). Thromboembolic complications occurred in 70% of HIT patients, but in none of non-HIT patients (14/20 v 0/20, p = 0.001). Intensive care unit stay was longer in HIT patients than in controls (16.5 [11.0] v 1.0 [3.0] days, p < 0.001). Nine HIT patients died (45%), while all control patients survived. Mortality was related to thrombotic complications in seven HIT patients (35%).
CONCLUSIONS: The incidence of HIT in association with low-molecular-weight heparin use after cardiac surgery was low. HIT was associated with perioperative platelet transfusions and carried a remarkably high risk of thromboembolic complications and death. In order to reduce morbidity and mortality, early recognition of heparin-associated antiplatelet antibodies and alternative anticoagulation strategies need to be implemented.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17289474     DOI: 10.1053/j.jvca.2006.05.002

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  5 in total

1.  Death due to undetected heparin-induced thrombocytopenia after cardiac surgery.

Authors:  Nobuyuki Yamamoto; Masaki Nie; Yosuke Hari; Kuniyoshi Ohara; Kagami Miyaji
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-05-25

2.  Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study.

Authors:  Jack C J Sun; Kevin H T Teoh; Tej Sheth; David Landry; Hyejung Jung; Theodore E Warkentin; Salim Yusuf; Andre Lamy; John W Eikelboom
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

3.  The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery.

Authors:  I J Welsby; E F Krakow; J A Heit; E C Williams; G M Arepally; S Bar-Yosef; D F Kong; S Martinelli; I Dhakal; W W Liu; J Krischer; T L Ortel
Journal:  J Thromb Haemost       Date:  2016-11-30       Impact factor: 5.824

4.  Atherosclerosis is not a risk factor for anti-platelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery.

Authors:  Adam Cuker; Lubica Rauova; Douglas Bolgiano; William H Matthai; Mortimer Poncz; Barbara A Konkle
Journal:  Thromb Haemost       Date:  2014-01-30       Impact factor: 5.249

5.  Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery.

Authors:  T J Gluckman; J B Segal; S P Schulman; E P Shapiro; T S Kickler; M M Prechel; J V Conte; J M Walenga; I Shafique; J J Rade
Journal:  J Thromb Haemost       Date:  2009-06-23       Impact factor: 5.824

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.